Bion-1301 phase 3
WebNov 4, 2024 · Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular … WebJun 8, 2024 · Part 3 of the ongoing phase 1/2 multi-center trial (see www.clinicaltrials.gov, identifier NCT03945318) is evaluating the safety, tolerability, PK and pharmacodynamics …
Bion-1301 phase 3
Did you know?
WebNov 4, 2024 · Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody, is being evaluated in a phase 1/2 trial for IgA nephropathy. WebNov 4, 2024 · Chinook will host a live conference call and webcast today at 4:30 pm EDT to discuss the data from Cohort 1 of Part 3 of Chinook’s ongoing phase 1/2 study of BION-1301 in patients with IgAN as ...
Web2 days ago · Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and proteinuric glomerular diseases. … WebNov 4, 2024 · These data reinforce our confidence in the dose and schedule we have selected to take forward in the phase 3 trial of BION-1301 for patients with IgAN that we plan to initiate next year.”
WebJan 3, 2024 · According to GlobalData, the latest event to affect BION-1301’s likelihood of approval (LoA) and phase transition for IgA Nephropathy (Berger’s Disease) took place on 07 Jul 2024, which increased the likelihood that the drug progresses to the next phase in its clinical pathway. GlobalData uses proprietary data and analytics to provide a ... WebBION-1301 Publications. Updated Interim Results of a Phase 1/2 Study of BION-1301 in Patients with IgA Nephropathy ISN World Congress of Nephrology 2024 March 2024. A Phase 1/2 Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults with IgA …
WebJun 6, 2024 · The Phase 1 trial described here will characterize the safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of BION-1301 in healthy volunteers (HV) and patients with IgAN. ... Parts 1 and 2 assess BION-1301 in HV, and Part 3 will assess BION-1301 in patients with IgAN. Parts 1 and 2 are double-blind, randomized, placebo …
WebDec 8, 2024 · A single-dose non-human primate study administering intravenous BION-1301 at 0.3, 3 and 30 mg/kg dose levels, yielded PK parameters typical for IgG4 class antibodies and absence of tolerability issues. ... Following identification of a recommended Phase 2 dose, an expanded cohort will investigate clinical activity of single-agent BION-1301. The ... glasses make my eyes tiredWebNov 4, 2024 · These data reinforce our confidence in the dose and schedule we have selected to take forward in the phase 3 trial of BION-1301 for patients with IgAN that we … glasses lord of the flies symbolismWebNov 4, 2024 · Data was presented from Cohort 1 in Part 3 of the ongoing phase 1/2 multi-center trial (see www.clinicaltrials.gov, identifier NCT03945318) evaluating the safety, … glasses on and off memeWeb1 day ago · SEATTLE, April 13, 2024 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development... glasses look youngerWebNov 4, 2024 · FR-PO659 – Updated Interim Results of a Phase 1/2 Study of BION-1301 in Patients with IgA Nephropathy BION-1301 is a novel anti-APRIL monoclonal antibody currently in phase 2 clinical ... glassesnow promo codeWeb3 BION-1301 3 3 30 4 BION-1301 3 3 100 26-Week Study with Bi-weekly Intravenous Dosing (14 doses) Group Treatment No. of Animals Dose Level Male Female (mg/kg/dose) ... (dosing phase) • Maximum measured reduction of fAPRIL of –63% was observed, with 5/8, 8/8, and 11/12 animals dropping BQL by end of study in low, mid, high dose groups ... glasses liverpool streetWebAug 31, 2024 · BION-1301 offers them a second shot on goal with superior potency. Key readouts for both assets are approaching in 2024. ... Ongoing PROTECT phase 3 study met its interim primary endpoint at 49.8% ... glasses make things look smaller